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Several important studies related to the treatment of atrial
fibrillation (AF) were published in the past year. In addi-
tion, building on recent data, the American College of
Cardiology Foundation (ACCF), the American Heart As-
sociation (AHA), and the Heart Rhythm Society (HRS)
provided updates to the AF guidelines.
Van Gelder et al. (1) published the RACE II (Rate
Control Efficacy in Permanent Atrial Fibrillation II) trial,
the first formal assessment of alternative rate control goals in
AF. Six hundred and fourteen patients in the Netherlands
were enrolled in this prospective, multicenter, randomized,
open-label, noninferiority trial and randomly assigned to a
“lenient rate-control” strategy (target resting heart rate
110 beats/min) versus a “strict rate-control” strategy
(target resting heart rate 80 beats/min and a target heart
rate 110 beats/min during moderate exercise). Rate con-
trol was achieved during a dose-adjustment phase by the use
of 1 or more negative dromotropic drugs, including beta-
blockers, nondihydropyridine calcium-channel blockers,
and digoxin, at various doses. The primary endpoint was a
composite of death from cardiovascular causes, hospitaliza-
tion for heart failure (HF), stroke, systemic embolism,
major bleeding, arrhythmic events including syncope, sus-
tained ventricular tachycardia (VT), cardiac arrest, life-
threatening adverse effects of rate control drugs, and inser-
tion of a pacemaker and implantable cardioverter-
defibrillator (ICD). To test the hypothesis that a lenient
rate-control strategy would be noninferior to strict rate
control, the power of the study was based on the ability to
exclude an absolute increase in 10 percentage points in the
rate of the primary outcome at 2.5 years in the lenient-
control group. At enrollment, participants had to have
permanent AF for up to 12 months, with a mean resting
heart rate 80 beats/min, and receiving anticoagulant
herapy dictated by thromboembolic risk factors. Impor-
ant exclusion criteria included New York Heart Associ-
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hospital admission, or cardiac surgery within the previous
3 months (2).
The baseline characteristics of the patients were generally
well balanced, with the exception of more coronary artery
disease, statin use, and higher diastolic blood pressure in the
lenient-control group. The mean resting heart rate was
93  9 beats/min in the lenient-control group compared to
6  12 beats/min in the strict-control group (p  0.001).
total of 81 patients (38 in the lenient-control group and
3 in the strict-control group) reached the primary out-
ome. The 3-year estimated cumulative incidence of the
rimary outcome was 12.9% in the lenient-control group
nd 14.9% in the strict-control group, resulting in an
bsolute difference between lenient control and strict control
f 2 percentage points (90% confidence interval [CI]:
7.6 to 3.5 percentage points). The criteria for noninferi-
rity in the lenient-control group was achieved with a
value 0.001. These results did not meaningfully change
fter adjustment for covariates that were not well balanced
etween the groups. In addition, no differences in the
eports of various AF-related symptoms were observed.
inally, fewer visits were required to achieve the target heart
ate in the lenient-control group (median of 0 compared to
edian of 2 for the strict-control group).
This study suggests that a lenient rate-control approach
argeting resting heart rates 110 beats/min may be rea-
onable and more easily achieved in AF patients compared
o the conventionally recommended target of 80 beats/min.
everal caveats should be considered before applying this
roadly to clinical practice. First, as patients with a recent
F hospitalization were excluded, these results may not
pply to such patients. Second, the adverse effects of
rolonged faster ventricular rates may require several years,
nd follow-up was terminated in this study after a maximum
f 3 years. In fact, as the primary outcome was specifically
ime to first occurrence of the composite outcome (meaning
articipants were censored after that first outcome), the
umulative effects of these strategies for patients who
xperienced 1 of the many adverse events that comprised
hat composite outcome is not known. Third, whereas 98%
f patients in the lenient-group achieved the target heart
ate, only 67% in the strict-control group achieved their
arget heart rate—this may have reduced the power to detect
n advantage (or disadvantage) of the “on treatment” out-
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that “lenient” still required a heart rate 110 beats/min.
Given promising, but conflicting, data regarding the
efficacy of omega-3 fatty acid supplementation for the
prevention of AF recurrence, Kowey et al. (3) randomly
allocated 663 AF patients stratified by a baseline diagnosis
of paroxysmal AF or persistent AF in a ratio of 5:1 to 4 g a
day of prescription omega-3 or placebo in a double-blind,
multicenter trial. Patients with persistent AF had to have
been successfully pharmacologically or electrically cardio-
verted, and the presence of sinus rhythm at study entry was
required for all participants. Each 1 g of the prescription
omega-3 included approximately 465 mg of eicosapenta-
enoic acid and 375 mg of docosahexaenoic acid. Patients
receiving antiarrhythmic drugs, patients taking omega-3
fatty acids within 30 days of enrollment, and patients with
specific structural heart disease were excluded. Five hundred
and eighty-four participants (88% of those enrolled) com-
pleted the 6-month study. The baseline characteristics and
proportions with paroxysmal and persistent AF were gen-
erally well balanced between the treatment groups. No
statistical difference was noted in the primary endpoint of
first symptomatic recurrence of AF or atrial flutter: in
patients with paroxysmal AF, there were 129 events (48%)
in the placebo group and 135 (52%) in the prescription
group (hazard ratio [HR]: 1.15, 95% CI: 0.90 to 1.46, p 
0.26). In patients with persistent AF, 33% of the placebo
group and 50% of the prescription drug group achieved this
primary endpoint (HR: 1.64, 95% CI: 0.92 to 2.92). Of
note, these outcomes were examined in multiple ways (in-
cluding with and without a pre-specified intention to treat
analysis and including analyses within multiple subgroups),
without any detection of benefit in the prescription arm.
Interestingly, patients receiving the prescription omega-3
fatty acid exhibited a statistically significantly lower average
heart rate during the first occurrence of symptomatic AF or
atrial flutter compared to patients on placebo, with a mean
difference of 6.99 beats/min (95% CI: 13.12 to 0.64
beats/min, p  0.03).
Although this study suggests there is no benefit of
mega-3 fatty acid prescription to prevent recurrent AF,
here are several limitations that should be considered. First,
ollow-up was limited to 6 months. This likely provides
mple evidence that an acute and efficacious electrophysi-
logic effect is not present, but chronic anti-inflammatory or
ntifibrotic effects that might reduce the risk of AF over
onger follow-up may still be present. In addition, the
rimary endpoint involved only symptomatic episodes, and
otential differences in the true underlying AF burden (and
ong-term sequelae of AF such as stroke) between groups
emain unknown. However, that ventricular rates during
trial arrhythmia episodes were slower in the prescription
roup may suggest that the chances of asymptomatic epi-
odes would be higher in that group. Although the study
as powered based on event rate estimates that were higherhan those actually observed (potentially resulting in a type II Kerror or false negative results), the point estimates generally
favored placebo, making such a type II error in favor of the
prescription unlikely. Finally, as acknowledged by the au-
thors, this study does not exclude the possibility of benefit in
other more specific AF populations, such as patients with
severe heart disease or patients in the post-operative setting.
Several important studies involving new ways to think
about and prevent stroke in AF were published in the last
year. First, a large trial of a factor Xa inhibitor in AF was
published. Connolly et al. (4) published the AVERROES
(Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in
Atrial Fibrillation Patients Who Have Failed or Are Un-
suitable for Vitamin K Antagonist Treatment) trial, in
which 5,599 AF patients with at least 1 additional risk
factor for stroke not receiving vitamin K antagonist therapy
(either because it had already been demonstrated to be
unsuitable or because it was expected to be unsuitable) were
randomly assigned to the direct factor Xa inhibitor, apixa-
ban, 5 mg twice daily, or aspirin at a dose of 81 to 324 mg
daily. A reduced dose of apixaban of 2.5 mg twice daily was
used for participants who were older than 80 years of age,
had a body weight of 60 kg or less, or a serum creatinine of
1.5 mg/dl or higher. The primary efficacy outcome was the
occurrence of stroke or systemic embolism, and the primary
safety outcome was the occurrence of major bleeding.
The baseline characteristics were well balanced between
treatment groups. Two thousand sixteen (40%) participants
had previously received and discontinued a vitamin K
antagonist. In 43% of cases, the physician had determined
that international normalized ratio (INR) measurements
could not be or were unlikely to be maintained, and vitamin
K antagonist therapy was considered unsuitable in 21%
because the risk of stroke was only moderate (a CHADS2
score of 1). In 15%, the only reason vitamin K antagonists
were unsuitable was because the patient did not want to take
them. The study was terminated early with a mean
follow-up duration of 1.1 years for an interim analysis that
met the pre-specified stopping rule for efficacy in favor of
apixaban. There were 51 primary outcome events (1.6% per
year) in the apixaban group and 113 (3.7% per year) in the
aspirin group (HR with apixaban: 0.45, 95% CI: 0.32 to
0.62, p  0.001). There were 44 major bleeding events
1.4% per year) in the apixaban group and 39 (1.2% per
ear) in the aspirin group (HR with apixaban: 1.13, 95% CI:
.74 to 1.75, p  0.57). While no significant differences in
emorrhagic stroke were observed, more minor bleeding
ith apixaban occurred with borderline statistical signifi-
ance (HR: 1.24, 95% CI: 1.00 to 1.53, p  0.05). The risk
f permanent discontinuation was 12% lower in the apixa-
an group (HR: 0.88, 95% CI: 0.78 to 0.99). Serial liver
unction tests revealed no differences between the groups. In
ultiple subgroup analyses, the superior efficacy of apixaban
ith similar adverse events was generally consistent.
It appears that, in AF patients with at least 1 additional
isk factor for stroke that are deemed unsuitable for vitamin
antagonist therapy, treatment with apixaban compared to
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increasing the risk of bleeding. It is important to understand
that the study was stopped early for efficacy. Although that
may reflect true efficacy that surpassed the initial power
estimates, chance may have played a role. However, the
study was stopped only after meeting very stringent stop-
ping rules that had been pre-specified. Conversely, the
shorter study period may have been insufficient to detect a
cumulative risk of bleeding or other adverse events with this
new drug. In addition, while these findings will likely be
applicable to a substantial number of AF patients currently
prescribed aspirin, future studies comparing the drug to
warfarin or the newer direct thrombin inhibitors are neces-
sary to inform us regarding the broader application of this
therapy.
Theoretically, a successful AF ablation might reduce the
long-term risk of stroke. However, an important study
published this year suggests that the procedure itself may
substantially increase the risk for asymptomatic cerebral
thromboembolism (5). Gaita et al. (5) performed magnetic
resonance imaging (MRI) of the brains of 234 consecutive
AF patients from 3 centers 1 day before and 1 day after AF
ablation. The CHADS2 score was 0 in 46% and 1 in 43%.
he ablation procedures were generally standard. In all
atients, a transesophageal echocardiogram was used to
xclude left atrial thrombus before proceeding with the
rocedure. A control group of 65 patients undergoing
ardioversion, all with standard precautions for stroke pro-
hylaxis, also underwent the same serial brain MRI studies.
one of the cardioversion patients exhibited either a clinical
troke or evidence of new ischemic cerebral lesions by MRI.
ne AF ablation patient experienced a transient ischemic
ttack (0.4%, a number compatible with and even lower
han previous reports [6]). However, asymptomatic new
schemic lesions were noted in the brains of 33 (14%)
atients: 25 were cortical, 7 were in the cerebellum, and 1
as in the basal ganglia. In all 33, a neurologic examination
as negative, and carotid Doppler studies showed no
ignificant abnormalities. Independent risk factors for these
symptomatic ischemic lesions included cardioversion dur-
ng the procedure and an activated clotting time (ACT)
alue 250 s. Mechanisms of intraprocedural thromboem-
olism might be related to char formation at the site of
adiofrequency delivery, thrombus formation on catheters or
heaths, air embolism, or thrombus formation immediately
fter cardioversion (7,8). It important to note that, although
he goal ACT between 250 and 300 s was in accordance
ith the Venice International Consensus on AF ablation
9), the HRS guidelines, citing previous studies demonstrat-
ng the risk of in situ thrombosis adherent to transseptal
heaths, recommend maintaining ACTs between 300 and
50 s (10). Cardioversion may have posed higher risks
ecause the resultant atrial stunning compounded the pro-
hrombotic effects of ablation or perhaps because more
blation lesions were delivered to the more persistent AF
atients that ultimately required cardioversion. Althoughhe neurologic examinations were normal, those lesions may
esult in more subtle but still clinically meaningful long-
erm consequences, particularly in these patients who are
ikely at risk for recurrent cerebral events.
At the end of an AF ablation case, there is typically a gap
n anticoagulation therapy between sheath removal and
noxaparin or heparin administration to reduce the risk of
atheter access site bleeding, potentially increasing the risks
or periprocedural thromboembolism as described in the
receding text. Therefore, it is worth noting an interesting
eport from Di Biase et al. (11) published in the last year,
escribing the outcomes of 2,618 AF ablation patients in
hom the ablation was performed on therapeutic warfarin
INR 2). Compared to patients bridged with enoxaparin,
atients maintained on warfarin exhibited significantly
ewer periprocedural strokes or transient ischemic attacks:
7 (1.1%, 95% CI: 0.72% to 1.58%) of 2,488 undergoing
blation with an 8-mm catheter after warfarin was discon-
inued; 12 (0.9%, 95% CI: 0.46% to 1.56%) of 1,348
ndergoing ablation with a 3.5-mm open-irrigated catheter
fter warfarin was discontinued; and 0 of 2,618 undergoing
blation with a 3.5 mm open-irrigated catheter while on
herapeutic warfarin (p  0.05). There were no differences
n major bleeding or frequency of pericardial effusion.
owever, pericardial effusion patients on therapeutic war-
arin more often required fresh frozen plasma (p  0.001),
required a median larger number of blood units for trans-
fusions (p  0.043), and had a larger volume of pericardial
aspiration (p  0.001) than did pericardial effusion patients
in whom warfarin had been discontinued. Although this
was a nonrandomized prospective observational study, the
on-warfarin patients had a higher prevalence of nonparox-
ysmal AF and more often had a CHADS2 score 2.
Although the relative timing of performing these proce-
dures is not described in the paper, one potential caveat is
that, if in fact the majority of on-warfarin procedures were
performed later, it is possible that the operators and insti-
tutions were more experienced performing the procedures
during a greater proportion of the on-warfarin cases versus
the off-warfarin cases. Regardless, consistent with some of
the practices in many electrophysiology groups that are
becoming more common, performing these cases on thera-
peutic warfarin appears to be a reasonable approach.
Two important studies reported long-term follow-up
results of AF ablation this past year. Interpretation of the
results is complex, given frequent repeat ablation proce-
dures, variable patient characteristics, and variable types of
recurrences (macro–re-entrant atrial tachycardias versus AF).
In brief, Ouyang et al. (12) described 161 consecutive
paroxysmal AF patients with normal left ventricular (LV)
function undergoing AF ablation in Germany, finding that
stable sinus rhythm was present in 75 (47%) patients after
the first procedure with a median 4.8 years (range 0.33 to
5.5 years) of follow-up. However, after a median of 1 (range
1 to 3) procedures, stable sinus rhythm was achieved in 128
patients (80%) during a median follow-up of 4.6 years
1648 Marcus et al. JACC Vol. 58, No. 16, 2011
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rhythm patients continued to take antiarrhythmic drugs.
Weerasooriya et al. (13) reported the long-term results of
100 paroxysmal and persistent AF patients undergoing
ablation in Bordeaux, France. After a single ablation pro-
cedure, actuarial arrhythmia-free survival rates were 40 
5%, 37 5%, and 29 5% at 1, 2, and 5 years, respectively.
By a median of 5 years, 51% had undergone at least 1 repeat
ablation procedure. The actuarial survival rates after the last
ablation procedure were 87  4%, 81  4%, and 63  5%
at 1, 2, and 5 years, respectively. In both studies, recurrences
were most common in the first 6 months. Also, in both,
there was evidence of a steady rate of recurrence. These
studies suggest that AF ablation patients should be coun-
seled regarding the possibility of long-term recurrence and
the potential need for repeat procedures. Perhaps most
importantly, in accordance with current guidelines (10),
these studies show that AF ablation should not be consid-
ered an alternative to anticoagulation therapy for long-term
stroke prevention, particularly in patients at high risk for
stroke.
AF Guideline Updates
Several updates to the ACCF/AHA/HRS AF guidelines
were published this past year. Based on the RACE II trial
described in the preceding text (1), there is a new recom-
mendation for rate control during AF: designated as a Class
III recommendation, the 2011 ACCF/AHA/HRS AF
guidelines state that there is no benefit of treatment to
achieve strict versus lenient rate control as defined in the
preceding text (14). The guidelines restrict this recommen-
dation to patients with stable ventricular function (defined
as an ejection fraction 40%) and no or acceptable symp-
toms related to the arrhythmia. They also mention within
this recommendation that uncontrolled tachycardia over
time may be associated with a reversible decline in ventric-
ular performance. In large part due to evidence provided by
the ACTIVE-A (Atrial Fibrillation Clopidogrel Trial With
Irbesartan for Prevention of Vascular Events) trial (15), a
study reviewed in detail in last year’s Year in Clinical
Cardiac Electrophysiology (16), there is now a Class IIb
recommendation that clopidogrel may be added to aspirin to
reduce the risk of major vascular events, including stroke, in
AF patients for whom oral anticoagulation therapy with
warfarin is considered unsuitable due to patient preference
or the physician’s assessment of the patient’s ability to safely
sustain anticoagulation therapy (Level of Evidence: B) (14).
Based largely on findings from the ATHENA (A Placebo-
Controlled, Double-Blind, Parallel-Arm Trial to Assess the
Efficacy of Dronedarone 400 mg BID for the Prevention of
Cardiovascular Hospitalization or Death From Any Cause
in Patients With Atrial Fibrillation/Atrial Flutter) trial (17),
there is a new Class IIa recommendation that dronedarone
is reasonable to decrease the need for cardiovascular-related
hospitalizations in paroxysmal AF patients or after cardio-version of persistent AF (Level of Evidence: B) (14). And,
on the basis of the ANDROMEDA (Antiarrhythmic Trial
With Dronedarone in Moderate to Severe Congestive
Heart Failure Evaluating Morbidity Decrease) trial (18), a
Class III-Harm recommendation, dronedarone should not
be administered to patients with class IV heart failure or
patients with an episode of decompensated heart failure in
the past 4 weeks, especially in the setting of an LV ejection
fraction 35% (Level of Evidence: B) (14). In the revised
“Maintenance of Sinus Rhythm” flow chart, dronedarone is
now included along with flecainide, propafenone, and sota-
lol as a first-line antiarrhythmic drug choice for AF patients
with no or minimal heart disease (whether hypertension is
present or not) and along with dofetilide and sotalol for
patients with coronary artery disease (14).
On the basis of growing evidence from multiple studies,
several recommendations regarding catheter AF ablation
were refined in the updated guidelines. Although previously
a Class IIa recommendation with Level of Evidence: C,
catheter ablation performed in experienced centers is now a
Class I recommendation (Level of Evidence: A) as a means
to maintain sinus rhythm in significantly symptomatic,
paroxysmal AF patients who have failed an antiarrhythmic
drug and have normal or mildly dilated left atria, normal or
mildly reduced LV function, and no severe pulmonary
disease (14). As a Class IIa recommendation, catheter
ablation is now considered reasonable to treat symptomatic
persistent AF (Level of Evidence: A). And, as a Class IIb
recommendation, it is reasonable to use catheter ablation in
the treatment of symptomatic paroxysmal AF patients with
significant left atrial dilation with or without significant LV
dysfunction (Level of Evidence: A) (14).
Finally, in a separate focused ACCF/AHA/HRS guide-
line update dedicated to dabigatran in AF and based
primarily on the RE-LY (Randomized Evaluation of Long-
Term Anticoagulation Therapy) study (19) (reviewed in
detail in last year’s Year in Clinical Cardiac Electrophysi-
ology) (16), dabigatran now has a Class I recommendation
as a useful alternative to warfarin for the prevention of
stroke and systemic embolism in patients with AF and risk
factors for stroke or systemic embolization who do not have
a prosthetic heart valve or hemodynamically significant valve
disease, severe renal failure, or advanced liver disease (Level
of Evidence: B) (20).
Ventricular Arrhythmias
Weisfeldt et al. (21) performed a large epidemiologic study
investigating the underlying ventricular rhythms in patients
with cardiac arrest at home versus in a public setting. While
automated external defibrillators (AEDs) have been shown
to improve survival after out-of-hospital cardiac arrest in
public settings (22) (such as airports [23] and casinos [24]),
layperson use of AEDs in residential settings has not proved
to be of benefit (25), potentially because of a relatively low
prevalence of arrests due to ventricular fibrillation (VF) or
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of these “shockable rhythms” (VF and pulseless VT) may be
decreasing in general (26,27).
This was a prospective population-based cohort study
utilizing the Epidemiologic Cardiac Arrest Registry of the
Resuscitation Outcomes Consortium at 7 U.S. sites and 3
Canadian sites. From December 2005 to April 2007,
complete data were available on 14,509 nontraumatic car-
diac arrest patients for whom external defibrillation was
attempted by either lay bystanders or emergency medical
services (EMS) or who were treated with chest compres-
sions by EMS alone. The initial cardiac-arrest rhythm was
known for 12,930 patients (92%). To compare arrests that
occurred at home versus public settings, the primary analy-
ses excluded the 1,324 patients with an arrest in a residential
institution (such as a nursing home) or other private (not
home) locations. The median time from the 911 call to
EMS arrival was 5.0 min (interquartile range [IQR]: 3.6 to
6.6 min) for arrests in public and 5.6 min (IQR: 4.3 to 7.1
min) for arrests at home. The initial ascertainable rhythm
was VF or pulseless VT (and, in rare cases, a hypotensive
supraventricular tachycardia) in 3,336 of the 12,930 arrests
(26%). Of the 3,451 patients with arrests at home, 1,193
(35%) had VF or pulseless VT compared with 600 of 1,003
(60%) with an arrest in a public location. After adjusting for
age, sex, bystander-administered CPR, and time from 911
call to the arrival of EMS, there was a 2.28 greater odds of
initial VF or pulseless VT in a public location versus at
home (95% CI: 1.96 to 2.66 greater odds, p 0.001). After
restricting the analysis to bystander-applied AEDs, 25 of 69
(36%) patients with arrests in the home compared to 125 of
159 (79%) patients with arrests in public were found to have
a shockable rhythm (after multivariable adjustment, there
was a 4.48 greater odds of a shockable rhythm in patients
with an arrest in public, 95% CI: 2.23 to 8.97 greater odds,
p  0.001). Survival was generally better for patients with
ardiac arrests in public compared to those with arrests at
ome. These findings may help explain the disparate find-
ngs regarding success in saving lives with AEDs in public
ersus no proven substantial benefit of these devices when
sed in private homes. The exact reasons why less VF/
ulseless is observed as the initial rhythm at home remain
nknown. The researchers suggest that patients who arrest
t home are typically older and more likely to have chronic
iseases that limit activities outside the home. The reported
iming from initial arrest to arrival of EMS personnel was
rovided by bystanders and may not have reflected the true
ime—for example, it is not clear how the timing of a
witnessed” event in a patient who had been sleeping would
ave been counted, whereas presumably all or most of the
ublic arrests may have resulted in a more dramatic and
bvious collapse more amenable to a rapid 911 call. The
uthors conclude that, given the relatively low incidence of
hockable arrhythmias in the home cardiac arrests, treat-
ent strategies at home emphasizing prompt and high 0uality bystander-delivered CPR may be as effective as the
idespread deployment of AEDs in homes.
A second important study on ventricular arrhythmias and
udden death published this past year sought to understand
he apparent paradox regarding the poor performance of
rimary prevention ICDs in preventing death within the
rst month after a myocardial infarction (MI). Although
udden (presumed arrhythmic) death remains an important
ause of death after MI, with the highest risk occurring
hortly after the MI, randomized trials assessing ICD
mplant within the first month after MI have failed to show
ny mortality benefit (28,29). Pouler et al. (30) studied all of
he available autopsy reports of deceased patients that
articipated in VALIANT (Valsartan in Acute Myocardial
nfarction Trial) (30). The VALIANT trial randomly
llocated 14,703 patients with clinical evidence of heart
ailure or LV dysfunction (ejection fraction 35% by
chocardiography or ventriculography, or ejection fraction
40% by radionuclide imaging), or both, after an acute MI
o valsartan, captopril, or both. There were 2,878 deaths
ver a median follow-up of 24.7 months. At the discretion
f treating physicians and according to local practices, an
utopsy was performed in 444 (15%) of the deaths, and
eports were available for 398 patients. Compared to pa-
ients who died without an autopsy, patients who under-
ent an autopsy were younger, more often white, had
igher diastolic blood pressures, and were more likely to
ave a history of hypertension; and they were less likely to
ave diabetes mellitus, dyslipidemia, or to have undergone a
rimary percutaneous angioplasty. The majority of patients
ith autopsies performed (65%) were in Russia, where
andated autopsies were more common. By clinical infor-
ation only, 105 (26%) were classified as dying suddenly
nd unexpectedly. Of these 105, 54 (51%) had no specific
utopsy evidence of cause of death other than the index
I and were, therefore, presumed to have died of a
entricular arrhythmia. Six (6%) died within 1 week of the
I: 3 had myocardial rupture and 3 were only found to have
vidence of the index MI (death attributed to arrhythmia).
wenty-eight (27%) of the 105 patients had specific evi-
ence of recurrent MI, 10 (10%) had cardiac rupture, 4 (4%)
ad evidence of overwhelming pulmonary congestion, 2
2%) had evidence of stroke or pulmonary embolism, and 1
1%) had evidence of a drug overdose. The autopsy records
esulted in the reclassification of the cause of death in 69
17%) of the 398 patients, mostly because of previously
nrecognized fatal MI or myocardial rupture in patients
ho died suddenly. Importantly, the percentage of sudden
eaths due to recurrent MI or myocardial rupture was
ighest in the first month and then declined substantially
ver time. In contrast, the percentage of likely true arrhyth-
ic deaths increased significantly over time. Specifically,
ithin the first month, only 20% of sudden deaths were
resumed due to arrhythmia, whereas 75% of all sudden
eaths after 3 months were assumed to be arrhythmic (p 
.0001). These data are compatible with and may in fact
1650 Marcus et al. JACC Vol. 58, No. 16, 2011
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mortality benefit of ICDs early after MI (28,29), and further
supports the current guideline to wait at least 40 days after
an MI before implanting an ICD (31).
Cardiac Resynchronization Therapy
The RAFT (Resynchronization-Defibrillation for Ambula-
tory Heart Failure Trial) study reconfirmed that the addi-
tion of cardiac resynchronization therapy (CRT) to an ICD
provided additional benefits for mild-to-moderate HF pa-
tients (32). In this multicenter clinical trial, 1,798 NYHA
functional class II and III patients with LVEF 30% and
QRS duration 120 ms on optimal medical therapy were
randomly assigned to receive either an ICD or cardiac
resynchronization therapy with defibrillator (CRT-D). Ap-
proximately one-third of the patients had nonischemic
cardiomyopathy and 71% to 73% had left bundle branch
block (LBBB). The mean QRS duration was 157 ms. The
primary endpoint was death from any cause or hospitaliza-
tion for HF. During a mean follow-up period of 40 months,
there were significantly more patients in the ICD group
reaching the primary endpoint than in the CRT-D group
(40.3% vs. 33.2%; HR: 0.75). However, device-related
complications occurred twice as often in the CRT-D group,
most commonly due to LV lead dislodgement and infection.
In contrast to findings from the MADIT-CRT (Multi-
center Automatic Defibrillator Implantation Trial–Cardiac
Resynchronization Therapy) study, CRT-D resulted in
additional mortality benefit when compared to the ICD
alone.
Several subsequent reports from the MADIT-CRT trial
greatly advanced our understanding of CRT in HF (33). In
a subgroup analysis of MADIT-CRT patients (NYHA
functional class I or II and LVEF 30%, QRS 130 ms),
when compared with ICD-only therapy, CRT-D provided
significantly more benefits (reduction in HF event or death,
LV volume, and risk of ventricular tachyarrhythmias, and
improvement in LVEF) only in patients with LBBB (34). It
was suggested that more generalized dyssynchrony was
present with LBBB because of abnormal activation of the
interventricular septum and markedly delayed activation of
the lateral LV. Consequently, more reverse remodeling
from better resynchronization led to better clinical outcome
in LBBB patients. This finding prompted the Circulatory
System Devices Panel of the U.S. Food and Drug Admin-
istration to recommend approval of CRT-D therapy to
patients who met the MADIT-CRT study enrollment
criteria with an added requirement that these patients
also have LBBB. The improvement in clinical outcomes
from CRT-D was found to link directly to reverse remod-
eling from resynchronization pacing (35). The CRT signif-
icantly reduced cardiac size (left ventricular end-diastolic
volume [LVEDV] and left ventricular end-systolic volume
[LVESV] indexes) and improved performance (LVEF). A
10% decrease in LVEDV was associated with a 40% riskreduction. Sex was also a factor in clinical outcomes: women
in the MADIT-CRT trial benefited more from CRT, with
greater reductions in death or heart failure, all-cause mor-
tality, and greater improvement in reverse modeling (36).
The significance of bundle branch block morphology
and other predictors of CRT outcomes were further
examined in a retrospective analysis of data collected
during 2005 and 2006 from the Medicare Implantable
Cardioverter-Defibrillator Registry (37). The 14,946 pa-
tients with CRT-D had 1- and 3-year mortality rates of
12% and 32%, respectively. After age80 years and NYHA
functional class IV status, RBBB and ischemic cardiomy-
opathy were the next strongest predictor of mortality: death
was twice as high as in patients with LBBB and nonisch-
emic cardiomyopathy together. The role of HF etiology in
NYHA functional class I and II patients treated with CRT
was analyzed using data from the REVERSE (Resynchro-
nization Reverses Remodeling in Systolic Left Ventricular
Dysfunction Study) trial (38). The CRT significantly re-
duced the percentage of patients with the worsening HF
composite response in 277 nonischemic patients, but not in
333 ischemic patients. Reverse remodeling, as indicated by
the LVESV index, was greater in the nonischemic cardio-
myopathy patients. However, the latter group was more
often younger, female, had a LBBB and a longer QRS
duration, received beta-blockers, and exhibited several other
factors known to have favorable influence on CRT. Not
surprisingly, multivariable analysis showed that HF etiology
was not an independent predictor of a favorable response to
CRT. On the other hand, in a single-center study involving
503 patients, CRT resulted in greater reverse remodeling
(LVEF and LVEDV) and better 4-year survival for non-
ischemic cardiomyopathy (77%) than ischemic cardiomyop-
athy (44%) (39).
The question of what constitutes a CRT responder was
raised by a study in which 17 different primary response
criteria were identified from 26 relevant articles (40). Agree-
ment between different methods to define CRT responder
was found to be poor 75% of the time and strong only 4%
of the time. Nevertheless, taking all the published studies
together, the most likely suspect list for adverse clinical
predictors in CRT consists of advanced age, male sex,
ischemic cardiomyopathy, NYHA functional class IV
symptoms, non-LBBB, QRS 150 ms, significant LV
scarring, and severe noncardiac comorbidities such as pul-
monary disease, pulmonary hypertension, renal dysfunction,
and diabetes mellitus (41).
In addition to the preceding factors, LV pacing site is a
major determinant in successful CRT. The current consen-
sus is to position the LV lead in a lateral or posterolateral
branch of the coronary sinus. The MADIT-CRT study
data were analyzed for the effect of LV lead position on
clinical outcomes (42). The benefit was similar for leads in
the anterior, lateral, or posterior position. However, apical
lead location when compared to nonapical position was
associated with a significantly higher risk for the composite
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death alone (HR: 2.91). Apical LV pacing was associated
with a significantly worse clinical outcome in LBBB and
nonischemic cardiomyopathy. The degree of reverse remod-
eling from CRT was similar among all pacing sites, but a
trend toward less reverse remodeling was seen in apical LV
pacing. Interestingly, apical pacing was associated with a
worse outcome only in men, not in women. The most
important message of the study was that LV apical lead
placement should be avoided as much as possible because of
its detrimental effect. However, it is important to note that,
while the primary endpoint occurred more frequently with
apical pacing (22%) compared to nonapical pacing (13%), it
was lower than that observed in the ICD group (25.3%)
(33). Therefore, although patients with an existing apical
LV lead may not reap the maximal benefit from CRT, there
is no evidence from this study that it actively worsens the
clinical outcomes compared to patients treated with an ICD
alone.
Implantable Cardioverter-Defibrillators
The long-term mortality benefit of ICDs in primary pre-
vention was investigated in the MADIT-II study (43). In
he initial median follow-up of 1.5 years, treatment with an
CD reduced total mortality by 31%. This benefit was
ustained at 8 years of follow-up (34%). At 8 years, the
umulative probability of total mortality remained signifi-
antly lower among ICD patients (49%) than non-ICD
atients (62%). Compared to the first 3.5 years of follow-up,
t the end of 8 years, the average survival gain increased
rom 0.167 to 0.52 years and the number of ICD patients
eeded to save 1 life decreased from 17 to 8. The analysis
lso confirmed that right ventricular (RV) pacing in dual-
hamber ICD recipients in MADIT-II study patients
dversely affects long-term mortality. Whereas no signifi-
ant difference in mortality rate was detected between ICD
atients with low (50% pacing) and high (50%) RV
acing during the first 3 years, the increased mortality in the
igh RV pacing group from 3 to 8 years of follow-up
egated any apparent survival benefit of the ICD over that
eriod (44). Of significant interest is that the adverse effect
f high RV pacing was not found in the presence of LBBB.
mong non-LBBB patients, only low RV pacing was
ssociated with a significant reduction in mortality during
he 8-year follow-up period. A provocative corollary is that
V pacing may not be harmful to patients with systolic
ysfunction and LBBB, as the incremental dyssynchrony
nduced by RV pacing is likely much less significant.
ICD therapy is a Class IIb indication for patients with
rrhythmogenic right ventricular cardiomyopathy/dysplasia
ARVC) (45). A retrospective study involving 106 patients
ith ARVC who received an ICD because of 1 or more
rrhythmia risk factors that included syncope, nonsustained
T, familial sudden death, and sustained ventricular tachy-rrhythmias induced with electrophysiology testing wasperformed to better identify patients who would benefit
from ICD therapy. Syncope significantly predicted lifesav-
ing ICD intervention, and a history of nonsustained VT
(3 consecutive ventricular complexes with a rate of 100
beats/min, lasting 30 s recorded on 24-h Holter monitor-
ing or during exercise testing) signified intermediate risks.
Ventricular tachyarrhythmia inducibility had poor positive
and negative predictive values for ICD intervention, 35%
and 74%, respectively. None of the 27 asymptomatic pa-
tients with isolated familial sudden death had appropriate
ICD therapy. Inappropriate ICD therapy occurred in 19%,
and a device-related complication was observed in 17% of
the patients. The results of this study strongly support
prophylactic insertion of an ICD in AVRC patients with
syncope and serious consideration for patients with asymp-
tomatic, spontaneous nonsustained VT. The study suggests
that primary prevention ICDs may not be indicated in
asymptomatic ARVC patients with isolated familial sudden
death.
The DINAMIT (Defibrillation in Acute Myocardial
Infarction Trial) showed that implantation of ICDs within
6 to 40 days of MI reduced arrhythmic death but not
mortality among patients with low LVEF (35%) and low
heart rate variability (28). The reduction of arrhythmic
deaths (67%) was more than offset by an increase in
nonarrhythmic deaths (70% relative risks when compared to
non-ICD group). As in the preceding text, a recent autopsy
study has taught us more about the likely mechanisms of
death in this kind of patient population (30), and a recent
re-examination of the DINAMIT study data explored
whether the ICDs themselves may have resulted in some
harm (46). The most striking finding was that, after patients
received appropriate ICD therapy (70% shock), there was a
more than twofold increase in all-cause mortality (36%)
compared with either the control group (16%) or the ICD
group with no appropriate therapy (13%). Shocks are known
to be associated with higher mortality in the MADIT-II
and SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) patients. Patients with appropriate shocks in the
DINAMIT study also had more coexisting cardiac events
(MI and HF) than patients enrolled in the other 2 trials.
Ventricular tachyarrhythmias requiring shocks (30% VF),
especially during the first year after MI (68% occurrence),
may simply be a marker of more severe underlying cardiac
disease and a poorer prognosis. Only 26% of the studied
patients had in-hospital percutaneous transluminal coronary
angioplasty for MI, and the percentage receiving stents were
likely to be even smaller (patient enrollment occurred from
1998 to 2000). More availability of primary percutaneous
coronary intervention during acute MI may alter the out-
comes of similar patients in the future.
The REPLACE registry is the first prospective, multi-
center study designed to collect complication data in pa-
tients for 6 months after replacement of a pacemaker, ICD,
or CRT generator. Cohort 1 consisted of patients without
(1,031) and cohort 2 of patients with (713) a planned
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was significantly higher in cohort 2 (15.3%) than in cohort
1 (4.0%). In both groups, major complications were higher
among ICD than pacemaker replacements. Upgrading to or
lead revision in CRT devices carried the highest major
complication rate (18.7%). The 6-month infection rates
were relatively low and similar in cohort 1 (1.4%) and cohort
2 (1.1%). However, a combined complication rate of 11.2%
(4% for major and 7.2% for minor) over a 6-month period
is unexpectedly high in procedures that were limited to
generator replacements only. The combined rate jumped to
22.9% in concomitant lead revisions, with twice as many
major than minor complications.
Remote Device Monitoring
Remote monitoring with full-interrogation of ICDs was
first introduced in 2001 and extended to pacemakers in
2009. Wireless technology enables automatic device inter-
rogation at scheduled intervals and transmission of data
when triggered by alert events. Evidence for the benefit of
remote monitoring was clearly demonstrated in 2 recent
prospective randomized, multicenter trials. In the TRUST
(Lumos-T Safely Reduces Routine Office Device Follow-up
Trial), ICD patients with daily 24-h continuous wireless
remote monitoring were compared to conventional in-office
visits (47). Remote monitoring significantly reduced visits
by 45% and enabled earlier detection of arrhythmic events
without any increased in adverse events (death, stroke, and
surgical intervention). In the CONNECT (Clinical Evalu-
ation of Remote Notification to Reduce Time to Clinical
Decision Trial), wireless remote monitoring of ICD pa-
tients significantly shortened event-to-clinical decision time
and mean length of hospitalization compared to conven-
tional device clinic visits, without adversely affecting mor-
tality, hospitalization frequency, emergency department, or
unscheduled clinic visits (48).
Translational Cardiac Electrophysiology
The long-QT syndromes are inherited diseases that are
characterized by prolongation of the QT interval and risk of
syncope and/or sudden death due to ventricular arrhyth-
mias. To date, 12 genes have been identified and hundreds
of mutations have been described (49). Most of the muta-
tions involve loss of function of K channels (particularly
Ks and IKr) or gain of function of the Na channels and,
ore rarely, involvement of Ca channels (50). Hereto-
fore, channel function has been studied in heterologous
systems (i.e., human embryonic kidney cells, and so forth) or
mice or rabbit models. The relationship of these models to
human cardiac cells has not been defined.
Recently, 3 studies have described the use of cardiac-
induced pluripotential stem cells (IPSC) to simulate various
forms of the long-QT syndrome. The first report came from
Moretti et al. (51) who, in a landmark study, were able to
generate functional myocytes from members of a familywith a dominant missense mutation (R190Q) in the
KCNQ1 gene, which encodes for the Iks channel. Cells are
prepared from the patients skin biopsy, and fibroblasts are
induced to differentiate into pluripotential stem cells which
are further coaxed to develop into cardiac myocytes (52,53).
The authors were able to study both cell aggregates as well
as individual cells from control subjects and the LQT1
patients. Microelectrode measurement of the respective
action potentials showed that the LQT1 myocytes had a
substantially longer action potential duration and a 75% to
80% reduction in the Iks current due to altered activation
and deactivation of channel function. In addition, they
showed that catecholamine-induced arrhythmias were at-
tenuated with beta-blockers. This study confirms previous
studies using heterologous systems and replicates well-
known clinical observations (54).
The next report by Itzhaki et al. (55) described similar
studies using fibroblasts from a patient with a missense
mutation in the KCNH2 gene (A614V), which encodes the
Ikr channel. The authors found prolongation of the action
potential duration in myocytes with the KCNH2 mutation
compared to controls. Voltage clamp studies documented
significant loss of Ikr current. Of interest was the finding of
spontaneous early after depolarizations or even torsades de
pointes recorded from surrogate extracellular electrocardio-
graphic recording system (field potential duration). In a
series of elegant studies, the authors exposed the control and
affected myocytes with agents likely to enhance (K
channel-blockers E401 or cisapride) or ameliorate channel-
blockade (i.e., KATP channel-openers, Ca channel-
lockade and ranolazine, alate Na channel-blocker). They
found the expected results based on previous clinical exper-
iments using heterologous systems. Of interest, ranolazine,
while not affecting action potential duration still blocked
induction of after depolarizations or arrhythmias. This
remarkable study clearly demonstrates the power of this
model to both replicate human disease processes and assess
drug effects.
A third study (56) using similar methodology was applied
to 2 patients with Timothy’s syndrome. A single missense
mutation involving the CACNAIC gene which encodes the
 subunit of the L-type Ca channel results in a pheno-
type characterized by prolongation of the QT interval,
syndactly, immune deficiency, and cognitive impairment
(57). The genetic mutation responsible for Timothy’s syn-
drome is associated with severe impairment of voltage-
dependant inactivation of the channel, leading to a gain of
function of the Ca current. The authors found that the
ffected myocytes had prolonged action potential duration,
xcess Ca influx, and irregular electrical activity on
intracellular recordings. Of great interest was the finding
that roscovitine, a compound known to increase voltage
dependant inactivation of the L-type Ca channel, re-
stored normal electrical function to the affected myocytes.
These 3 studies as a group have shown beautiful replication
of previous findings using heterologous systems and provide
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arrhythmias and testing of new therapies.
Arrhythmogenic RV Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is a
cardiomyopathy that results in fibrofatty replacement of
the RV wall. Important associated features are the
frequent incidence of ventricular arrhythmias, particularly
in athletes (57).
The molecular genetic basis of ARVC has been partially
elucidated. It is known, for example, that approximately
50% of patients have been shown to harbor a mutation in
the desmosomal genes. The desmosomes are responsible for
cell to cell adhesion, and it is postulated that the sheer stress
engendered by myocardial wall stress results in pulling apart
of cells and replacement with fibrofatty tissue. Mutations in
desmoplakin, plakoglobin, plakophilin 2, desmocillein 2,
and desmoglein 2 have been identified in nearly 50% of
affected patients. In addition, nondesmosomal genes (i.e.,
TMEM43 and TGFB3) have also been identified (58).
The molecular pathogenesis of ARVC has been advanced
y focusing on the effects of abnormal cellular localization of
esmosomal plakoglobin. The latter results in reduction of
anonical Wnt/-catenin signaling transcription factors,
hich favors diversion of RV myocyte production into fatty
nd fibrous tissue (60,61). A recent review emphasizes the
athogenesis of ARVC on the basis of alternation in cardiac
ignaling pathways (58).
Another milestone paper focused on load-reducing ther-
py in progression of ARVC in a plakoglobin-deficient
ouse model (61). The investigators studied littermates of
eterozygous plakoglobin mice (plako /) and wild type
ontrol mice who underwent 7 weeks of intense daily
wimming exercises. The mice were randomly allocated to
eceive load-reducing therapy consisting of nitrates and
iuretics or no treatment. The treated group also received
olsidomine to prevent nitrate tolerance. The authors
howed load-reduction therapy resulted in prevention of RV
ilation in the plako / mice. In addition, VT was more
often initiated in the untreated group, and mapping
studies suggested that the mechanism of VT was re-
entrant. This is the first study to use animal models as a
means to test therapeutic interventions for ARVC.
Whether the concept or specific drugs used will be
helpful in the clinical arena awaits further study. A
thoughtful and provocative accompanying editorial by
Calkins (62) is also worth reading.
Genetics and Molecular Biology of Pre-Excitation
Ventricular pre-excitation results from early activation of
the ventricles by accessory AV nodal pathways. The pre-
excitation pattern is usually associated with re-entrant ar-
rhythmias and is known as the Wolff-Parkinson-White
syndrome (WPW). To date, there are 3 known genes
associated with WPW in humans. The first gene discoveredwas a mutation in the PRAKG2 and subsequently in the
LAMP2 gene, which results in glycogen-storage myopathy
(63–65). Mutations of BMP2 have been recently associated
with WPW syndrome associated with cognitive dysfunction
or Alagille syndrome (66,67). More recently, the impor-
tance of the notch signaling pathway in both development
of the AV node as well as accessory pathways have been
reported (68). It was found that notch inhibition disrupts
AV nodal development, and invasive electrophysiologic
studies showed a shorter A-H interval in notch-inhibited
animals compared with controls. In contrast, gain of func-
tion of notch activity resulted in formation of an accessory
pathway.
Aanhaanen et al. (69) described the effects of Tbx2-
dependent changes in the development of the annulus. The
investigators showed that inactivation of Tbx2 by another
transcription factor (downstream to notch) required for
formation of the annulus fibrosus leads to the formation of
accessory pathways as well as malformation of the annulus.
They nicely inscribed patterns of ventricular pre-excitation
in these mice. They showed that affected mice expressed
connexin-40, and connexin-43 as well as Na channels in
the accessory pathways (all required for rapid conduction).
The latter 2 articles add a great deal to our understanding
of the normal development of the specialized conduction
system as well as the annulus. In addition, the depiction of
the accessory pathways are very similar to those described in
humans, in contrast to those observed in mice with muta-
tions in PRAKG2 or LAMP2.
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